Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Flaherty

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 25, 2013
The Cost of Hope: a candid roundtable discussionAmanda Bennett, Ronald M Bukowski, Keith Flaherty, et al.
International Journal of Oncology|September 24, 2019
Selective uveal melanoma inhibition with calcium channel blockadeMichael Shaughnessy, Grace Lamuraglia, Nikolai Klebanov, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2013
Modifying phase I methodology to facilitate enrolment of molecularly selected patientsAntoine Hollebecque, Sophie Postel-Vinay, Jaap Verweij, et al.
The Journal of Investigative Dermatology|November 7, 2020
Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF InhibitionZhenyu Ji, Ching-Ni Njauw, Samantha Guhan, et al.
The New England Journal of Medicine|January 24, 2009
Treatment of growing teratoma syndromeDavid J Vaughn, Keith Flaherty, Priti Lal, et al.
Cancer Research|May 3, 2017
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy ResponseBenjamin M Larimer, Eric Wehrenberg-Klee, Frank Dubois, et al.
Cancer Chemotherapy and Pharmacology|February 16, 2005
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumorsMaria Luisa Veronese, Keith Flaherty, Amy Kramer, et al.
Cancer|July 6, 2018
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanomaAlexander T Faje, Donald Lawrence, Keith Flaherty, et al.
The Journal of Investigative Dermatology|March 22, 2021
The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type MelanomaSamantha M Guhan, Michael Shaughnessy, Anpuchchelvi Rajadurai, et al.
Pigment Cell & Melanoma Research|March 28, 2013
Meeting report: The future of preclinical mouse models in melanoma treatment is nowGlenn Merlino, Keith Flaherty, Nicolas Acquavella, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Journal of the National Comprehensive Cancer Network : JNCCN|May 25, 2013
The Cost of Hope: a candid roundtable discussionAmanda Bennett, Ronald M Bukowski, Keith Flaherty, et al.
International Journal of Oncology|September 24, 2019
Selective uveal melanoma inhibition with calcium channel blockadeMichael Shaughnessy, Grace Lamuraglia, Nikolai Klebanov, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2013
Modifying phase I methodology to facilitate enrolment of molecularly selected patientsAntoine Hollebecque, Sophie Postel-Vinay, Jaap Verweij, et al.
The Journal of Investigative Dermatology|November 7, 2020
Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF InhibitionZhenyu Ji, Ching-Ni Njauw, Samantha Guhan, et al.
The New England Journal of Medicine|January 24, 2009
Treatment of growing teratoma syndromeDavid J Vaughn, Keith Flaherty, Priti Lal, et al.
Cancer Research|May 3, 2017
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy ResponseBenjamin M Larimer, Eric Wehrenberg-Klee, Frank Dubois, et al.
Cancer Chemotherapy and Pharmacology|February 16, 2005
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumorsMaria Luisa Veronese, Keith Flaherty, Amy Kramer, et al.
Cancer|July 6, 2018
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanomaAlexander T Faje, Donald Lawrence, Keith Flaherty, et al.
The Journal of Investigative Dermatology|March 22, 2021
The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type MelanomaSamantha M Guhan, Michael Shaughnessy, Anpuchchelvi Rajadurai, et al.
Pigment Cell & Melanoma Research|March 28, 2013
Meeting report: The future of preclinical mouse models in melanoma treatment is nowGlenn Merlino, Keith Flaherty, Nicolas Acquavella, et al.
Pageof 7